Ovarian Neoplasms Clinical Trials

278 clinical trials for Ovarian Neoplasms across international registries, including 42 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) — RECRUITING · PHASE3
• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma — RECRUITING · PHASE1
• A Study of DM002 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer — RECRUITING · PHASE3
• A Study of LY4337713 in Participants With FAP-Positive Solid Tumors — RECRUITING · PHASE1
• Centralization and Oncologic Outcomes in Ovarian Cancer — RECRUITING
• A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) — RECRUITING · PHASE3
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study — RECRUITING · PHASE2
• A Study of LY4170156 in Participants With Selected Advanced Solid Tumors — RECRUITING · PHASE1
• Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer — RECRUITING · NA
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression — RECRUITING · PHASE1
• Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing — RECRUITING
• A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer — RECRUITING · PHASE1
• A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) — RECRUITING · PHASE2
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions — RECRUITING · NA
• Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II) — RECRUITING · PHASE3
• OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study — RECRUITING · NA
• DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations — RECRUITING · PHASE2
• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. — RECRUITING · PHASE2
• Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer — RECRUITING
• Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques — RECRUITING
• A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration — RECRUITING
• DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics — RECRUITING
• Ultrasound-guided Transvaginal Aspiration of Cystic Pelvic Lesions — RECRUITING
• Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer — RECRUITING · NA
• Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass — RECRUITING
• Improved Diagnosis of Ovarian Cancer — RECRUITING
• Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker — RECRUITING
• Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. — RECRUITING · PHASE2
• Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer — RECRUITING · NA
• Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer — RECRUITING · PHASE2
• TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors — RECRUITING · PHASE3
• TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors — RECRUITING · PHASE3
• Establishment of a Tumor Bank for Tissue Samples — RECRUITING
• Establishment of a Tumor Bank for Blood Samples — RECRUITING
• Retrospective Study of Brachytherapy — RECRUITING
• KOrean Borderline Ovarian Tumor (KOBOT) Registry — RECRUITING
• Institut Paoli Calmettes Ovarian Cancer Database — RECRUITING
• Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants — NOT_YET_RECRUITING · NA
• A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — ACTIVE_NOT_RECRUITING · PHASE1
• Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03] — NOT_YET_RECRUITING · PHASE3
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) — NOT_YET_RECRUITING · PHASE3
• A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer — TERMINATED · PHASE1
• A Study of SGN-MesoC2 in Advanced Solid Tumors — TERMINATED · PHASE1
• Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy — NOT_YET_RECRUITING

Refine this search